LU91314I9 - - Google Patents

Info

Publication number
LU91314I9
LU91314I9 LU91314C LU91314C LU91314I9 LU 91314 I9 LU91314 I9 LU 91314I9 LU 91314 C LU91314 C LU 91314C LU 91314 C LU91314 C LU 91314C LU 91314 I9 LU91314 I9 LU 91314I9
Authority
LU
Luxembourg
Prior art keywords
vlps
particles
papillomavirus
disassembled
virus
Prior art date
Application number
LU91314C
Other languages
English (en)
Other versions
LU91314I2 (fr
Inventor
Michael P Mccarthy
Joann Suzich
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Publication of LU91314I2 publication Critical patent/LU91314I2/fr
Publication of LU91314I9 publication Critical patent/LU91314I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
LU91314C 1997-09-05 2007-02-21 "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )" LU91314I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92399797A 1997-09-05 1997-09-05
PCT/US1998/016464 WO1999013056A1 (fr) 1997-09-05 1998-08-19 Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus

Publications (2)

Publication Number Publication Date
LU91314I2 LU91314I2 (fr) 2007-04-23
LU91314I9 true LU91314I9 (fr) 2019-01-30

Family

ID=25449564

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91314C LU91314I2 (fr) 1997-09-05 2007-02-21 "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"

Country Status (15)

Country Link
US (2) US6416945B1 (fr)
EP (2) EP1015561B1 (fr)
JP (2) JP4199416B2 (fr)
AT (1) ATE333501T1 (fr)
AU (1) AU742409B2 (fr)
CA (1) CA2302545C (fr)
CY (2) CY1107987T1 (fr)
DE (3) DE122007000015I1 (fr)
DK (1) DK1015561T3 (fr)
ES (2) ES2268787T3 (fr)
FR (1) FR07C0012I2 (fr)
LU (1) LU91314I2 (fr)
NL (1) NL300264I2 (fr)
PT (1) PT1015561E (fr)
WO (1) WO1999013056A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
JP2000515741A (ja) * 1996-07-17 2000-11-28 アメリカ合衆国 感染性パピローマウイルス偽ウイルス粒子
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
WO2001042780A1 (fr) 1999-12-09 2001-06-14 Medimmune, Inc. Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
ATE418997T1 (de) * 2000-07-06 2009-01-15 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
WO2002024961A1 (fr) * 2000-09-18 2002-03-28 Medimmune, Inc. Dosage in vitro destine a mesurer l'antigenicite d'un vaccin
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US7041500B2 (en) * 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10224111A1 (de) * 2002-05-29 2003-12-18 November Ag Molekulare Medizin Verfahren zum Assemblieren von Untereinheiten zu Kapsoiden
CA2486118A1 (fr) 2002-06-07 2003-12-18 Large Scale Biology Corporation Ensemble de vaccins adaptable et plate-forme d'administration de vaccins
KR101361769B1 (ko) 2002-12-20 2014-02-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신
EP1785433A4 (fr) 2004-07-01 2008-10-01 Tokyo Inst Tech Construction ressemblant a une particule virale et procede servant a former celle-ci dans des conditions physiologiques
CN101287489A (zh) * 2005-06-01 2008-10-15 陶氏环球技术公司 多价病毒样颗粒的生产
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
CA2685308A1 (fr) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Production amelioree et assemblage in vivo de particules icosaedriques solubles recombinees analogues a un virus
HUE030437T2 (en) 2007-05-08 2017-05-29 Us Health Papillomavirus pseudoviruses for detection and therapy of tumors
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
ES2845212T3 (es) 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
CN102497880A (zh) 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
SG176887A1 (en) * 2009-07-03 2012-01-30 Univ Queensland A method of preparation of a biological particulate structure
WO2011039646A2 (fr) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Ciblage de particules d'administration de gène de papillomavirus
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
WO2013139744A1 (fr) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Procédé de vaccination contre le papillomavirus humain
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP4059521A1 (fr) 2013-09-18 2022-09-21 Aura Biosciences, Inc. Conjugués de particules de type viral pour le diagnostic et le traitement de tumeurs
MA40624A (fr) * 2014-09-11 2016-03-17 Cadila Healthcare Ltd Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
RU2677336C2 (ru) * 2014-12-26 2019-01-16 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
CN108473950A (zh) 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
WO2017075537A1 (fr) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions et méthodes pour le du traitement du cancer
CA3059882A1 (fr) 2017-04-12 2018-10-18 Aura Biosciences, Inc. Polytherapie ciblee
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
EP3706783A1 (fr) 2017-11-06 2020-09-16 The United States of America, as represented by the Secretary, Department of Health and Human Services Traitement du cancer utilisant une immunité antimicrobienne préexistante
WO2019096796A1 (fr) 2017-11-14 2019-05-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Papillomavirus non humains pour administration de gènes in vitro et in vivo
KR20230038465A (ko) * 2020-06-09 2023-03-20 아이코사백스, 인크. 2성분 바이러스 유사 입자를 조립하는 방법
GB202011609D0 (en) 2020-07-27 2020-09-09 Univ Leeds Innovations Ltd Coronaviral packaging signals
JP2026000483A (ja) * 2022-11-22 2026-01-06 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン
WO2026055208A1 (fr) 2024-09-04 2026-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugués de pseudo-particules virales comprenant des composés de colorants photoactivables et leurs procédés de préparation et d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016638A1 (fr) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Vehicules de transduction pour le transfert de l'adn a une cellule de mammifere
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique

Also Published As

Publication number Publication date
AU9015498A (en) 1999-03-29
EP1015561B1 (fr) 2006-07-19
EP1015561A1 (fr) 2000-07-05
JP2009057377A (ja) 2009-03-19
FR07C0012I2 (fr) 2007-10-26
ES2268787T3 (es) 2007-03-16
CA2302545C (fr) 2012-04-03
DE69835294T2 (de) 2007-07-26
EP1700911A1 (fr) 2006-09-13
EP1700911B1 (fr) 2016-04-06
DE122007000015I2 (de) 2008-01-24
NL300264I1 (nl) 2007-05-01
PT1015561E (pt) 2006-11-30
ATE333501T1 (de) 2006-08-15
HK1030797A1 (en) 2001-05-18
NL300264I2 (nl) 2008-06-02
LU91314I2 (fr) 2007-04-23
DE69835294D1 (de) 2006-08-31
FR07C0012I1 (fr) 2007-03-30
JP4199416B2 (ja) 2008-12-17
DE122007000015I1 (de) 2007-05-24
CY2007007I2 (el) 2016-10-05
CY2007007I1 (el) 2009-11-04
DK1015561T3 (da) 2006-11-13
CY1107987T1 (el) 2011-04-06
JP2001515922A (ja) 2001-09-25
JP4486142B2 (ja) 2010-06-23
WO1999013056A1 (fr) 1999-03-18
AU742409B2 (en) 2002-01-03
ES2572628T3 (es) 2016-06-01
US6416945B1 (en) 2002-07-09
CA2302545A1 (fr) 1999-03-18
US6261765B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
FR07C0012I1 (fr)
NZ509610A (en) Process for purifying human papillomavirus virus-like particles using hydroxyapatite
PL317234A1 (en) Vaccines against papilloma virus
EP1394259A3 (fr) Virus ARM récombinant, infectieux, non-segmenté, brin-negatif
FR11C0022I1 (fr)
AU5998400A (en) In vitro reconstitution of segmented negative-strand rna viruses
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
WO2003078455A3 (fr) Vaccin
AU5873696A (en) Method of preparing 3-haloalkyl-1h-pyrazoles
AU2127395A (en) Highly efficient production and isolation of viral particles
IL148371A0 (en) Process to separate 1,3-propanediol or glycerol, or a mixture thereof from a biological mixture
NZ305188A (en) DNA encoding Human Papilloma Virus (hPV)type 18
JO2243B1 (en) Prepare a 6.3-dicyl-6.5-dihydro-4 hydroxy-pyran-2-one compound
AU2002213901A1 (en) Method for regenerating a zeolite catalyst
AUPM358894A0 (en) Modified papilloma virus l2 protein and vlps formed therefrom
AU6193800A (en) Method of producing a microwave filter, and microwave filter produced according to this method
AU2001245737A1 (en) Method of recovering 1,3-propanediol from fermentation broth
JPH10276792A5 (fr)
AU4457397A (en) Model for the papilloma virus infection (in vivo), consisting of the scid-bo mouse
HU9701546D0 (en) Catalyst, method for producing those and method for catalyc purifying outgas of dmt production
AU2001234085A1 (en) Process for the preparation of a mucosal form of the eosinophil cationic protein (ecp), mucosal ecp and uses thereof as allergic phlogosis marker
EP0955367A3 (fr) Nucleoproteines recombinantes du virus Toscana
MX9802486A (es) Proteina de helicobacter pylori.
AU2001280313A1 (en) Carbon black, method of production thereof and a reactor for producing carbon black.